

## BreastScreen<sup>®</sup> Riferimenti Bibliografici

1. National Cancer Institute. Cancer Stat Fact Sheets. Accessed October 22, 2014; Available from: <http://seer.cancer.gov/>.
2. National Cancer Institute. Accessed October 22, 2014; Available from: <http://www.cancer.gov/>.
3. Castera, L., et al., Next-generation sequencing for the diagnosis of hereditary breast and ovarian cancer using genomic capture targeting multiple candidate genes. *Eur J Hum Genet*, 2014. 22(11): p. 1305-13.
4. Walsh, T., et al., Detection of inherited mutations for breast and ovarian cancer using genomic capture and massively parallel sequencing. *Proc Natl Acad Sci U S A*, 2010. 107(28): p. 12629-33.
5. van der Groep, P., E. van der Wall, and P.J. van Diest, Pathology of hereditary breast cancer. *Cell Oncol (Dordr)*, 2011. 34(2): p. 71-88.
6. Walsh, T. and M.C. King, Ten genes for inherited breast cancer. *Cancer Cell*, 2007. 11(2): p. 103-5.
7. Meindl, A., et al., Hereditary breast and ovarian cancer: new genes, new treatments, new concepts. *Dtsch Arztebl Int*, 2011. 108(19): p. 323-30.
8. Antoniou, A., et al., Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case Series unselected for family history: a combined analysis of 22 studies. *Am J Hum Genet*, 2003. 72(5): p. 1117-30.
9. Chen, S. and G. Parmigiani, Meta-analysis of BRCA1 and BRCA2 penetrance. *J Clin Oncol*, 2007. 25(11): p. 1329-33.
10. Ford, D., et al., Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. The Breast Cancer Linkage Consortium. *Am J Hum Genet*, 1998. 62(3): p. 676-89.
11. Loveday, C., et al., Germline RAD51C mutations confer susceptibility to ovarian cancer. *Nat Genet*, 2012. 44(5): p. 475-6; author reply 476.
12. Olivier, M., et al., Li-Fraumeni and related syndromes: correlation between tumor type, family structure, and TP53 genotype. *Cancer Res*, 2003. 63(20): p. 6643-50.
13. Renwick, A., et al., ATM mutations that cause ataxia-telangiectasia are breast cancer susceptibility alleles. *Nat Genet*, 2006. 38(8): p. 873-5.
14. Roberts NJ, J.Y., Yu J, Kopelovich L, Petersen GM, Bondy ML, Steven Gallinger, Schwartz AG, Syngal S, Cote ML, Axilbund J, Schlick R, Ali SZ, Eshleman JR, Velculescu VE, Goggins M, Bert Vogelstein, Papadopoulos M, Hruban RH, Kinzler KW, Klein AP, ATM Mutations in Patients with hereditary Pancreatic cancer. *Cancer Discovery*, 2011. 2(1): p. OF1-OF6.
15. Janavicius, R., Founder BRCA1/2 mutations in the Europe: implications for hereditary breast-ovarian cancer prevention and control. *EPMA J*, 2010. 1(3): p. 397-412.
16. Ferla, R., et al., Founder mutations in BRCA1 and BRCA2 genes. *Ann Oncol*, 2007. 18 Suppl 6: p. vi93-8.
17. Tulinius, H., et al., The effect of a single BRCA2 mutation on cancer in Iceland. *J Med Genet*, 2002. 39(7): p. 457-62.

18. Tai, Y.C., et al., Breast cancer risk among male BRCA1 and BRCA2 mutation carriers. *J Natl Cancer Inst*, 2007. 99(23): p. 1811-4.
19. Thompson, D., D.F. Easton, and C. Breast Cancer Linkage, Cancer Incidence in BRCA1 mutation carriers. *J Natl Cancer Inst*, 2002. 94(18): p. 1358-65.
20. Folkins, A.K. and T.A. Longacre, Hereditary gynaecological malignancies: advances in screening and treatment. *Histopathology*, 2013. 62(1): p. 2-30.
21. Shannon, K.M. and A. Chittenden, Genetic testing by cancer site: breast. *Cancer J*, 2012. 18(4): p. 310-9.
22. Kote-Jarai, Z., et al., BRCA2 is a moderate penetrance gene contributing to young-onset prostate cancer: implications for genetic testing in prostate cancer patients. *Br J Cancer*, 2011. 105(8): p. 1230-4.
23. van Asperen, C.J., et al., Cancer risks in BRCA2 families: estimates for sites other than breast and ovary. *J Med Genet*, 2005. 42(9): p. 711-9.
24. Damiola, F., et al., Rare key functional domain missense substitutions in MRE11A, RAD50, and NBN contribute to breast cancer susceptibility: results from a Breast Cancer Family Registry case-control mutation-screening study. *Breast Cancer Res*, 2014. 16(3): p. R58.
25. Pennington, K.P. and E.M. Swisher, Hereditary ovarian cancer: beyond the usual suspects. *Gynecol Oncol*, 2012. 124(2): p. 347-53.
26. Seal, S., et al., Truncating mutations in the Fanconi anemia J gene BRIP1 are low-penetrance breast cancer susceptibility alleles. *Nat Genet*, 2006. 38(11): p. 1239-41.
27. Walsh, T., et al., Mutations in 12 genes for inherited ovarian, fallopian tube, and peritoneal carcinoma identified by massively parallel sequencing. *Proc Natl Acad Sci U S A*, 2011. 108(44): p. 18032-7.
28. Loveday, C., et al., Germline mutations in RAD51D confer susceptibility to ovarian cancer. *Nat Genet*, 2011. 43(9): p. 879-82.
29. Meindl, A., et al., Germline mutations in breast and ovarian cancer pedigrees establish RAD51C as a human cancer susceptibility gene. *Nat Genet*, 2010. 42(5): p. 410-4.
30. Bahassi, E.M., et al., The checkpoint kinases Chk1 and Chk2 regulate the functional associations between hBRCA2 and Rad51 in response to DNA damage. *Oncogene*, 2008. 27(28): p. 3977-85.
31. Cybulski, C., et al., CHEK2 is a multiorgan cancer susceptibility gene. *Am J Hum Genet*, 2004. 75(6): p. 1131-5.
32. Walsh, T., et al., Spectrum of mutations in BRCA1, BRCA2, CHEK2, and TP53 in families at high risk of breast cancer. *Jama*, 2006. 295(12): p. 1379-88.
33. Pharoah, P.D., et al., Incidence of gastric cancer and breast cancer in CDH1 (E-cadherin) mutation carriers from hereditary diffuse gastric cancer families. *Gastroenterology*, 2001. 121(6): p. 1348-53.
34. Guilford, P., B. Humar, and V. Blair, Hereditary diffuse gastric cancer: translation of CDH1 germline mutations into clinical practice. *Gastric Cancer*, 2010. 13(1): p. 1-10.